1	State of Arkansas	As Engrossed: $S4/1/19$ ABill	
2	92nd General Assembly	A DIII	
3	Regular Session, 2019		SENATE BILL 634
4			
5	By: Senator Bledsoe		
6	By: Representative D. Ferguson	n	
7 8		For An Act To Be Entitled	
9	AN ACT TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO		
10	COVER OPIOID ANTAGONISTS AS A PHARMACY BENEFIT; AND		
10	FOR OTHER PURPOSES.		
12	FOR OTHER I		
13			
14		Subtitle	
15	TO REC	QUIRE THE ARKANSAS MEDICAID PROGRAM	1
16	TO COV	VER OPIOID ANTAGONISTS AS A PHARMAG	Ϋ́Υ
17	BENEF	IT.	
18			
19			
20	BE IT ENACTED BY THE GE	NERAL ASSEMBLY OF THE STATE OF ARK	ANSAS:
21			
22	SECTION 1. Arkan	asas Code Title 20, Chapter 77, Sub	chapter 4, is
23	amended to add an additional section to read as follows:		
24	<u>20-77-406. Opioi</u>	<u>d antagonist.</u>	
25	<u>(a) The Arkansas</u>	<u>Medicaid Program:</u>	
26	<u>(1) Shall</u>	cover any drug approved on or befo	<u>re the effective</u>
27	<u>date of this section by</u>	the United States Food and Drug A	dministration as an
28	<u>opioid antagonist for t</u>	the prevention of relapse to opioid	dependence and
29	<u>other substance use dis</u>	sorders; and	
30	<u>(2) May:</u>		
31	<u>(A)</u>	Cover any drug approved after the	effective date of
32	this section by the United States Food and Drug Administration as an opioid		
33	antagonist for the prevention of relapse to opioid dependence and other		
34	substance use disorders; and		
35	<u>(B)</u>	Replace a covered opioid antagonis	t for the prevention
36	of relapse to opioid de	ependence and other substance use d	isorders that has



.

As Engrossed: S4/1/19

1	been approved by the United States Food and Drug Administration with another		
2	opioid antagonist if the other opioid antagonist is:		
3	(i) Approved by the United States Food and Drug		
4	Administration for the prevention of relapse to opioid dependence and other		
5	substance use disorders;		
6	(ii) Proven to be more effective treatment for the		
7	prevention of relapse to opioid dependence and other substance use disorders		
8	than the existing covered opioid antagonist; and		
9	(iii) Proven to be more cost-effective than the		
10	existing covered opioid antagonist.		
11	(b) Coverage as described under subsection (a) of this section shall		
12	be a pharmacy benefit under the Arkansas Medicaid Program.		
13			
14			
15	/s/Bledsoe		
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			

2